Risk of death from blood clot rises along with TV time, study finds
Those active about 2.5 hours a week had 25 percent lower disease risk than those who weren't, study found
Because it's winter in Brazil, mosquito activity has subsided
Don’t be fooled by the health halo that hangs over seemingly good-for-you foods. Many of them are anything but.
Large study should allay fears that procedure might play a role, researchers say
The smartphone-based character-hunting craze that's sweeping the world has caught the attention of a researcher at the University of Leicester, UK, specializing in international diabetes research. In fact, Dr Tom Yates sees the application as a potential means of tackling sedentary lifestyles and obesity, which can lead to type 2 diabetes. The augmented reality mobile game has so far been downloaded 75 million times worldwide, and sees users chase Pokémon characters through the streets.
Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said. India's Sun Pharmaceutical Industries Ltd and three buyout firms are also eyeing the venture, Laboratório Teut|Pfizer, said the people, who asked for anonymity since the process is in early stages. Brazil's Melo family owns the remaining 60 percent of Teuto|Pfizer, Latin America's largest pharmaceutical plant.
By Elaine Lies and Kwiyeon Ha SAGAMIHARA, Japan (Reuters) - A knife-wielding man broke into a facility for the disabled in a small town near Tokyo early on Tuesday and killed 19 patients as they slept, authorities said, Japan's worst mass killing since World War Two. At least 25 other residents were wounded in the attack at the Tsukui Yamayuri-En facility for mentally and physically disabled in Sagamihara town, about 25 miles (40 km) southwest of Tokyo. "This is a very heart-wrenching and shocking incident in which many innocent people became victims," Chief Cabinet Secretary Yoshihide Suga told a regular news conference in Tokyo.
(Reuters) - Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by sales of newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade thanks to its growing roster of medicines. The Indianapolis drugmaker, whose earnings growth resumed last year after three years of tumbling sales caused by competition from generic drugs, said investors can count on annual dividend increases in 2016 and beyond. Revenue rose 9 percent to $5.4 billion in the second quarter, topping Wall Street estimates of $5.15 billion.